Fortis Capital Management LLC Buys Shares of 16,606 Altimmune, Inc. (NASDAQ:ALT)

Fortis Capital Management LLC bought a new stake in Altimmune, Inc. (NASDAQ:ALT) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 16,606 shares of the company’s stock, valued at approximately $120,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new position in Altimmune in the fourth quarter valued at about $93,000. KLP Kapitalforvaltning AS purchased a new position in Altimmune in the fourth quarter valued at about $81,000. American Century Companies Inc. boosted its holdings in Altimmune by 35.8% in the fourth quarter. American Century Companies Inc. now owns 44,742 shares of the company’s stock worth $323,000 after acquiring an additional 11,788 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Altimmune by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock worth $153,000 after acquiring an additional 3,423 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in Altimmune by 36.7% in the fourth quarter. Intech Investment Management LLC now owns 46,123 shares of the company’s stock worth $333,000 after acquiring an additional 12,385 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Tuesday, March 18th. Stifel Nicolaus assumed coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Insider Activity at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by company insiders.

Altimmune Trading Up 0.2 %

Shares of ALT stock opened at $5.79 on Friday. The stock has a 50 day moving average of $6.33 and a 200 day moving average of $7.08. The stock has a market cap of $446.14 million, a P/E ratio of -3.74 and a beta of 0.87. Altimmune, Inc. has a twelve month low of $5.14 and a twelve month high of $11.16.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, research analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.